Why the study?
Does chronic propafenone dosing lead to metabolite cumulation in patients with frequent ventricular ectopy?
Does chronic propafenone dosing lead to metabolite cumulation in patients with frequent ventricular ectopy?
Propafenone metabolites 5-OHP and NDPP cumulate in the plasma during chronic oral therapy, suggesting a need to elucidate their clinical role.
Answers are grounded in this paper and cite their sources.
Chronic propafenone may cause metabolite cumulation; hypothesis-generating for clinical effects in ventricular ectopy.
The cumulation of propafenone and two of its metabolites, 5-hydroxypropafenone (5-OHP) and N-depropylpropafenone (NDPP), was examined in patients with frequent ventricular ectopy. After 2 weeks of propafenone therapy (300 mg twice a day), propafenone was discontinued and blood samples were drawn for 24 hours. The mean (+/- SD) steady-state concentrations of propafenone, 5-OHP, and NDPP were 1010 +/- 411, 174 +/- 113, and 179 +/- 93 ng/ml. The concentration ratios of 5-OHP/propafenone and NDPP/propafenone were 0.177 +/- 0.049 and 0.227 +/- 0.203. Plasma concentrations of 5-OHP and NDPP did not decay in a log-linear manner during the sampling period and thus estimates of their disappearance t1/2s were not possible. At 24 hours after propafenone dosing, concentrations of 5-OHP and NDPP were 63% +/- 37% and 50% +/- 21% of their mean steady-state levels. Our data indicate that these propafenone metabolites cumulate in the plasma during chronic oral propafenone therapy, and that their clinical role needs to be elucidated.
No takes yet. Share an insight, caveat, or question.
Kates et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: